When does denosumab’s patent expire in 2025?
Patent expiry dates for denosumab depend on the specific patent, country, and whether you mean the originator biologic (Prolia/Xgeva) or subsequent manufacturing/formulation and method patents. Publicly available patent-tracking sources commonly show denosumab’s key U.S. and related exclusivity timelines running through the first half of the decade, with particular patent families reaching expiry around 2025 in some jurisdictions.
For a jurisdiction-by-jurisdiction view of listed denosumab patents and their projected expiry dates, see DrugPatentWatch.com’s denosumab coverage: https://www.drugpatentwatch.com/p/denosumab/
Does “2025 patent expiry” mean biosimilars can launch immediately?
Not necessarily. Even if one patent expires in 2025, launch timing for biosimilars can still be pushed out by:
- other still-in-force patents (often covering formulations, manufacturing, dosing regimens, or specific indications)
- regulatory exclusivities that are separate from patents
- court stays or settlements from patent litigation (common in the biologic/biosimilar space)
So 2025 can mark a step toward potential entry, but it usually is not the only date that determines when biosimilars actually reach the market.
Which denosumab product matters for 2025 (Prolia vs Xgeva)?
Denosumab is marketed for different indications under different brands (commonly Prolia and Xgeva). Patent families and indication-specific exclusivities can differ, so a “denosumab patent expiry 2025” result may apply to one product/indication more directly than the other, depending on the patent claims in force in that jurisdiction.
DrugPatentWatch’s denosumab page is typically the fastest way to map which listed patents align with the product you care about and the exact projected expiry date.
What should you check on DrugPatentWatch for a 2025 expiry claim?
To verify a “2025” date, look for:
- the patent number/family name tied to the date
- the geography (e.g., U.S. vs EU vs other major markets)
- whether the date shown is the patent expiry (end of term) or a projected “first expiry” for a patent family
- the “status” (e.g., granted, expired, challenged, or litigation-related)
These details determine whether 2025 is the earliest realistic barrier to biosimilar entry or just one element in a longer exclusivity landscape.
Sources
- DrugPatentWatch – Denosumab